BridgeBio raises $300 million through partial capped monetization of BEYONTTRA European royalty

June 30, 2025 10:45 PM AEST | By EODHD

Google News:

BridgeBio raises $300 million through partial capped monetization of BEYONTTRA European royalty — Image source: Kalkine Media

Recent News

HH Global expands global executive team appointing Matt Strawn as Chie...

Wingderm USA Takes the Lead at TAS 2025, Cementing Its Local Presence...

Cascale Annual Report Highlights Convening Power, Need for Accelerated...

RITFIT Launches Its First-Ever Physical Showroom in California: Usheri...

* BridgeBio Pharma (NASDAQ:BBIO [https://seekingalpha.com/symbol/BBIO]) announced on Monday it has sold a portion of royalties due to the company from sales of BEYONTTRA in Europe to HealthCare Royalty and funds managed by Blue Owl Capital (NYSE:OWL [https://seekingalpha.com/symbol/OWL]) for $300 million. * The company said the royalty financing agreement monetizes select anticipated royalties and provides immediate less-dilutive capital. * Under the terms of the agreement, BridgeBio has received $300 million from HCRx and Blue Owl managed funds in exchange for 60% of royalties on the first $500 million of annual BEYONTTRA net sales in Europe. * The agreement includes an initial cap of 1.45x. Once the applicable cap is met, no further payments will be owed to the investors, said the company.

* In March 2024, BridgeBio entered into an exclusive licensing agreement with Bayer Consumer Care AG to commercialize BEYONTTRA in Europe for the treatment for ATTR‑CM. To date, BridgeBio has received $210 million in upfront and regulatory milestones, and anticipates receiving a further $75 million in near-term milestone payments, along with tiered royalties starting in the low‑30% range on net sales of BEYONTTRA in Europe. * Acoramidis is approved in the U.S. as Attruby by the FDA and in Europe as BEYONTTRA by the European Commission. It is also approved as BEYONTTRA by the Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency, with all labels specifying near-complete stabilization of TTR.

* BBIO -0.80% premarket to $44.5. * Source: Press Release [https://seekingalpha.com/pr/20151503-bridgebio-raises-300-million-through-partial-capped-monetization-of-beyonttra-european] MORE ON BRIDGEBIO PHARMA, BLUE OWL CAPITAL * Blue Owl Capital: A Good Long-Term Investment [https://seekingalpha.com/article/4793321-blue-owl-capital-solid-long-term-investment] * Blue Owl Capital: Strong Brand Name, Bright Future [https://seekingalpha.com/article/4793115-blue-owl-capital-strong-brand-name-bright-future] * BridgeBio: New Data Bolsters The Bull Case [https://seekingalpha.com/article/4792210-bridgebio-new-data-bolsters-the-bull-case] * Blue Owl Technology Finance to list on NYSE under ticker “OTF” [https://seekingalpha.com/news/4455201-blue-owl-technology-finance-to-list-on-nyse-under-ticker-otf] * Blue Owl, Chirisa, and PowerHouse unveil next phase of $5B data center JV [https://seekingalpha.com/news/4452838-blue-owl-chirisa-and-powerhouse-unveil-next-phase-of-5b-data-center-jv]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.